Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

Research on pain management during placement of intrauterine devices (IUD) is lacking, but most studies so far indicate that ...

Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.

The findings, in which doublet immunotherapy added to standard FOLFOX chemotherapy did not improve progression-free survival, ...

Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...

All US states and territories had an obesity prevalence higher than 20%. Overall, the Midwest (36.0%) and South (34.7%) had ...

Hoping to skirt the slow pace of new drug development, researchers are leaning on AI to uncover fresh uses for known ...

Primary care physicians should ask about genitourinary symptoms in men and intervene early to try to get related chronic ...